MGC has an ambitious international research and development agenda. Research and development projects include preclinical, clinical and botanical, focused at the intersection of phytocannabinoid-derived medicines and the pharmaceutical industry. The Company undertakes research, itself and in collaboration with research institutes or universities in three main locations: Australia, Slovenia and Malta (under construction).
The Company’s Clinical Advisory Team is responsible for leading three main research and development areas: Neurology, Oncology and Autoimmune.
We will continue to harvest the product in Slovenia and Czech Republic, and utilize the raw material at our production facility, as well as provide the product globally. Our product is delivered to our Innovation and Derma departments to produce best in class products for sale and distribution around the world.